NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwire - September 11, 2012) -
Regenerative medicine company Avita Medical Ltd.
(ASX: AVH), (PINKSHEETS: AVMXF
), (OTCQX: AVMXY
) announced that nine separate presentations regarding ReCell® Spray-On Skin® are being delivered at the 16th Congress of the International Society for Burn Injuries (ISBI), a biennial meeting underway in Edinburgh, Scotland, from 9 - 13 September 2012. The ISBI is hosted by the British Burn Association and will incorporate the 45th British Burn Association Annual Meeting for 2012. Congress attendees include burns and reconstructive surgeons, specialized medical practitioners working in the burns area and other health professionals.
Eight papers featuring the use of ReCell in the treatment of burns or burn-related injuries are being presented at the 2012 ISBI.
Presented papers cover a range of topics including:
- use of ReCell in the treatment of paediatric burns and scalds;
- ReCell as a replacement for grafts in burns;
- ReCell used in reconstructive surgery;
- ReCell in combination with split-thickness grafts;
- ReCell in the treatment of facial burns; and
- An economic cost-benefit model for use of ReCell.
Presentations represent work done at key Centres of Excellence throughout Europe and include: St Eugenio Hospital, Rome, Italy; Pinderfields General Hospital, Wakefield, UK; The St Andrew's Centre for Burns and Plastic Surgery, Chelmsford, UK; Chelsea and Westminster Hospital, London, UK; Shriners Hospital for Children, Galveston, Texas, USA; and The Royal Perth Hospital, Perth, West Australia, Australia.
In addition, Professor Fiona Wood, inventor of the ReCell technology, will be chairing an ISBI symposium which will include panellists presenting on ReCell.
"The high profile of ReCell at this year's ISBI Congress -- featured in nine presentations by highly regarded burn and reconstructive surgeons -- is a clear testament to the growing acceptance of ReCell by key clinicians, the excellent results being achieved with our technology and ReCell's increasing inclusion as a core component in the surgeon's armamentarium," said Dr. William Dolphin, CEO of Avita Medical. "There were no presentations on ReCell at the 2008 ISBI Congress, a single ReCell presentation at the 2010 ISBI and this year nine presentations. ReCell is a disruptive technology and our commercialisation strategy of working closely with key opinion leaders and select clinics is proving itself to be highly effective."
ABOUT AVITA MEDICAL LTD.
Avita Medical (http://www.avitamedical.com/) develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell® Spray-On Skin™, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is on market and generating early revenues. ReCell is not available for sale in the United States; in the U.S. ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.